Sentences with phrase «hiv vaccine program»

From Vanderbilt HIV Vaccine Program in Nashville, TN: (left to right) community engagement coordinator Keith Richardson, administrative assistant Latifa DaSilva, and community engagement manager Vic Sorrell.

As community engagement manager at the Vanderbilt HIV Vaccine Program, Sorrell gives talks like this many times.

Yves Levy, ANRS HIV vaccine program, Paris, will be speaking on this second approach.

Ernestine Mefor Halle University of Yaounde II / Cameroon Virus Research Institute / International AIDS Vaccine Initiative / HIV Vaccine Program,, Cameroon

Not exact matches

The move has outraged the broader community because the U.S. Military HIV Research Program plays a unique role in AIDS vaccine development.

In a previously published paper, Barouch and colleagues, including Colonel Nelson L. Michael, MD, PhD, director of the Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) and Stephen Thomas, MD, Upstate Medical University, State University of New York, demonstrated that three different vaccine candidates provided robust protection against Zika virus in both mice and rhesus monkeys.

Global spending for HIV vaccine research increased from $ 186 million in 1997 to $ 759 million in 2005, according to the Joint United Nations Program on HIV / AIDS.

«In line with our company's commitment to address global health needs, we are committed to working with leading experts to develop a preventative HIV vaccine and our team is excited to advance this program into human clinical studies.»

While its primary focus is developing a globally effective HIV vaccine, the program provides prevention, care and treatment through the President's Emergency Plan for AIDS Relief.

Dr. Polonis has spent most of her 28 years of research experience associated with the Military HIV Research Program and focusing on HIV vaccine development.

This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program - led RV144 clinical trial in Thailand — the first study to demonstrate that a vaccine can protect people from HIV infection.

Researchers from the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) have found that an experimental heroin vaccine induced antibodies that prevented the drug from crossing the blood - brain barrier in mice and rats.

In the RV144 vaccine trial, led by the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, the efficacy at 3.5 - years was 31.2 %; however, a higher early effect (60 %) was seen at 12 months.

Dr. Pontiano Kaleebu, Chairman Africa AIDS Vaccine Program and Acting Director of Uganda Virus Research Institute, delivered a strong keynote address that reiterated the importance of an HIV vaccine, what it will take to develop an effective vaccine and how community members can help with the international Vaccine Program and Acting Director of Uganda Virus Research Institute, delivered a strong keynote address that reiterated the importance of an HIV vaccine, what it will take to develop an effective vaccine and how community members can help with the international vaccine, what it will take to develop an effective vaccine and how community members can help with the international vaccine and how community members can help with the international effort.

MHRP's international research program has six clinical research sites in the U.S., Africa and Asia, where it conducts HIV cohort studies, HIV vaccine trials and therapeutic studies.

The event included a scientific lecture on Thai HIV vaccine trial (RV 144) and presentations on milestones achieved over the decade (2002 — 2012) in the different programs.

Since immune responses to vaccines can differ around the world, these findings are encouraging for the development of an effective Ebola vaccine for Africa,» said Merlin Robb, M.D., Director for Clinical Research at the US Military HIV Research Program (MHRP), whose site in Uganda, Makerere University Walter Reed Project (MUWRP), conducted the study.

«It is critical that we know these vaccines are safe and immunogenic in the communities where they will be used in Africa,» said Lt. Col. Julie Ake, an infectious disease physician, U.S. Military HIV Research Program (MHRP) Principal Deputy and protocol chair for the international study.

For example, the UK government's program for tackling HIV and AIDS in the developing world, which was published shortly after the Bangkok meeting, makes the unqualified comment that the enterprise «will accelerate research and development of an effective vaccine.»

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) initiated a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime - boost Ebola vaccine regimen in both healthy and HIV - infected volunteers.

«This finding is consistent with a hypothesis generated out of the follow - up studies to the RV144 HIV vaccine trial in Thailand that showed the first efficacy in humans,» noted COL Nelson Michael, Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

The U.S. Military HIV Research Program is part of a public - private partnershipworking to improve the original RV144 vaccine and achieve higher levels of protection.

Scientists at the US Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) recently developed a vaccine that blocks the opioids in heroin from reaching the brain in mice and rats, offering a potential breakthrough in treating opioid addiction.

Immune responses of patients could point way forward for future vaccines.In the latest study, researchers involved with the trial at Mahidol University in Bangkok and the U.S. Military HIV Research Program in Washington DC assembled a team to scour the blood of trial participants for immune indicators that differed between 41 people who received the vaccine and contracted HIV and 205 participants who did not become infected.

Though a preventative vaccine for HIV does not yet exist, NIAID oversees a robust research program to develop and evaluate vaccine candidates.

Sanjay Gurunathan from Sanofi Pasteur, manufacturer of one of the vaccines used in RV144, said a new partnership of the US National Institute of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pVaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pvaccine efficacy from the 31.2 percent of the RV144 trial to 50 percent.

The lab is currently a part of a multi-institutional group working on developing a prophylactic HIV vaccine under a five year Integrated Preclinical / Clinical AIDS Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (vaccine under a five year Integrated Preclinical / Clinical AIDS Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (NIAID).

Vice President, Scientific Operations Herbert Kean, M.D., Family Endowed Chair Professor Director, HIV - 1 Immunopathogenesis Laboratory Professor, Translational Tumor Immunology Program Professor, Vaccine & Immunotherapy Center Associate Director for Shared Facilities, Wistar Cancer Center

Dr. Manak has extensive expertise in development and validation of in - house and commercial assays for HIV and related infectious diseases and their use in diagnostic, epidemiological, vaccine and therapeutic programs.